The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-viral antigen-based compositions. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Anti-viral antigen-based compositions is a key innovation area in pharmaceuticals
A viral antigen is a protein encoded by the viral genome that can be detected by a specific immunological response. Antibodies produced by the immune system attach to specific antigens and protect the body from infection by removing them.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 300+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-viral antigen-based compositions.
Key players in anti-viral antigen-based compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-viral antigen-based compositions
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|GSK||993||Unlock Company Profile|
|C. H. Boehringer Sohn||718||Unlock Company Profile|
|Johnson & Johnson||638||Unlock Company Profile|
|Sanofi||583||Unlock Company Profile|
|Merck & Co||552||Unlock Company Profile|
|Takeda Pharmaceutical||446||Unlock Company Profile|
|Zoetis||438||Unlock Company Profile|
|Pfizer||367||Unlock Company Profile|
|Valneva||283||Unlock Company Profile|
|F. Hoffmann-La Roche||261||Unlock Company Profile|
|Regeneron Pharmaceuticals||247||Unlock Company Profile|
|Gilead Sciences||182||Unlock Company Profile|
|Inovio Pharmaceuticals||156||Unlock Company Profile|
|United States Of America||149||Unlock Company Profile|
|Mitsubishi Chemical Group||140||Unlock Company Profile|
|Vertex Pharmaceuticals||135||Unlock Company Profile|
|Vir Biotechnology||129||Unlock Company Profile|
|VLP Therapeutics||129||Unlock Company Profile|
|Centre National de la Recherche Scientifique||129||Unlock Company Profile|
|AstraZeneca||124||Unlock Company Profile|
|National Research Council of Canada||124||Unlock Company Profile|
|Theraclone Sciences||122||Unlock Company Profile|
|US Department of Health and Human Services||121||Unlock Company Profile|
|X4 Pharmaceuticals||120||Unlock Company Profile|
|Curevac||115||Unlock Company Profile|
|Molecular Templates||111||Unlock Company Profile|
|United Nations Industrial Development Organization||102||Unlock Company Profile|
|Bristol-Myers Squibb||96||Unlock Company Profile|
|Moderna||94||Unlock Company Profile|
|Celltrion||80||Unlock Company Profile|
|Trellis Bioscience||77||Unlock Company Profile|
|Erasmus MC||77||Unlock Company Profile|
|Temasek Life Sciences Laboratory||77||Unlock Company Profile|
|MacroGenics||72||Unlock Company Profile|
|Meiji Holdings||68||Unlock Company Profile|
|Academia Sinica||65||Unlock Company Profile|
|Bharat Biotech||64||Unlock Company Profile|
|Pomona Ricerca||61||Unlock Company Profile|
|Eli Lilly and||60||Unlock Company Profile|
|Intervet||59||Unlock Company Profile|
|Oswaldo Cruz Foundation||59||Unlock Company Profile|
|Nitto Denko||59||Unlock Company Profile|
|AIMM Therapeutics||59||Unlock Company Profile|
|Compagnie Merieux Alliance||58||Unlock Company Profile|
|Les Laboratoires Servier||57||Unlock Company Profile|
|PanTheryx||55||Unlock Company Profile|
|Grifols||53||Unlock Company Profile|
|Novavax||52||Unlock Company Profile|
|Solon Eiendom||50||Unlock Company Profile|
|Geeks On Call||49||Unlock Company Profile|
Source: GlobalData Patent Analytics
GSK is one of the leading patent filers in anti-viral antigen-based compositions. GSK is a healthcare company that focuses on developing, manufacturing and commercialising pharmaceuticals, vaccines, and consumer healthcare products.. It offers drugs spanning therapeutic areas such as respiratory, oncology, immuno-inflammation, central nervous system (CNS), metabolic, cardiovascular, dermatology, bacterial infections, viral infections, including HIV, and rare diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles, and bacterial meningitis.
In terms of application diversity, HuVet bio is the top company, followed by AbbVie and Cedars-Sinai Health System. By means of geographic reach, Providence St. Joseph Health holds the top position. While eyeGene and Fundacion IrsiCaixa are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.